Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.45 Insider Own6.40% Shs Outstand53.62M Perf Week8.95%
Market Cap1.75B Forward P/E- EPS next Y-1.53 Insider Trans0.00% Shs Float51.19M Perf Month8.02%
Income-267.30M PEG- EPS next Q-0.36 Inst Own75.10% Short Float20.41% Perf Quarter-0.15%
Sales5.40M P/S323.81 EPS this Y-5.50% Inst Trans3.46% Short Ratio5.06 Perf Half Y-31.81%
Book/sh6.16 P/B5.29 EPS next Y38.80% ROA-80.50% Target Price62.29 Perf Year195.92%
Cash/sh5.93 P/C5.50 EPS next 5Y-0.20% ROE-106.30% 52W Range8.00 - 63.73 Perf YTD18.88%
Dividend- P/FCF- EPS past 5Y- ROI-75.60% 52W High-46.29% Beta1.44
Dividend %- Quick Ratio4.80 Sales past 5Y-35.10% Gross Margin97.60% 52W Low327.86% ATR1.33
Employees197 Current Ratio5.00 Sales Q/Q315.40% Oper. Margin- RSI (14)70.24 Volatility4.66% 4.23%
OptionableYes Debt/Eq0.05 EPS Q/Q-12.30% Profit Margin- Rel Volume2.11 Prev Close32.61
ShortableYes LT Debt/Eq0.02 EarningsApr 27 AMC Payout- Avg Volume2.07M Price34.23
Recom1.90 SMA2014.12% SMA5012.81% SMA2001.51% Volume3,590,026 Change4.96%
Apr-05-17Upgrade SunTrust Hold → Buy
Mar-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Mar-02-17Initiated Instinet Buy $84
Mar-01-17Reiterated RBC Capital Mkts Outperform $98 → $91
Feb-22-17Reiterated Needham Buy $81 → $78
Jan-04-17Reiterated Morgan Stanley Equal-Weight $53 → $33
Dec-22-16Initiated JP Morgan Overweight $40
Dec-20-16Initiated Goldman Neutral
Dec-16-16Reiterated RBC Capital Mkts Outperform $106 → $98
Dec-14-16Reiterated Jefferies Hold $46 → $32
Oct-28-16Reiterated RBC Capital Mkts Outperform $108 → $106
Oct-27-16Initiated Morgan Stanley Equal-Weight $53
Oct-18-16Initiated Credit Suisse Outperform $68
Oct-10-16Reiterated Wedbush Outperform $66 → $72
Sep-28-16Reiterated RBC Capital Mkts Outperform $83 → $108
Sep-20-16Reiterated Needham Buy $47 → $81
Sep-19-16Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $83
Sep-19-16Upgrade Jefferies Underperform → Hold
Sep-19-16Reiterated Robert W. Baird Outperform $23 → $102
Jul-22-16Reiterated Needham Buy $20 → $26
Apr-24-17 12:17PM  5 Earnings Short-Squeeze Plays: Twitter, Sarepta Therapeutics Included TheStreet.com
11:03AM  Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers TheStreet.com
Apr-23-17 01:11PM  Barron's Picks And Pans: Bank Stocks, O'Reilly Automotive, Sarepta And More Benzinga
Apr-22-17 12:50AM  [$$] Drugmaker Sarepta's Stock Could Double Barrons.com
Apr-19-17 03:18PM  Sarepta Therapeutics, Inc. Value Analysis (NASDAQ:SRPT) : April 19, 2017 Capital Cube
Apr-18-17 11:20AM  Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, Inc. (SRPT) PR Newswire
08:32AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : April 18, 2017 Capital Cube
07:30AM  FDA Drug Approvals on the Rise in 2017: Today's Research Reports on Sarepta Therapeutics and TG Therapeutics Accesswire
Apr-17-17 08:30AM  Sarepta Therapeutics to Announce First Quarter 2017 Financial Results and Recent Corporate Developments on April 27, 2017 GlobeNewswire
Apr-13-17 12:21PM  Shark Bites: You Don't Want to Play the Gambler Today TheStreet.com
Apr-12-17 04:42PM  Sarepta Therapeutics Stock History: A Biotech Roller-Coaster Ride Motley Fool
Apr-06-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Sarepta Therapeutics and Novavax Accesswire
Apr-05-17 05:00PM  Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
11:17AM  Why Sarepta Can Gain 45% Barrons.com
09:23AM  Biotech Movers: Sarepta, Bellicum, Novavax TheStreet.com
09:05AM  Sarepta Gets An Upgrade; Cardiac, Pulmonary Function Could Provide Added Clinical Support For Exondys Benzinga
Apr-03-17 11:00AM  Sarepta chief hands over CMO role to former Regeneron exec at bizjournals.com
11:00AM  Sarepta chief hands over CMO role to former Regeneron exec American City Business Journals
08:30AM  Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer GlobeNewswire
Mar-31-17 06:30PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
08:32AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets
03:44AM  Why Is Sarepta (SRPT) Down 2.7% Since the Last Earnings Report? Zacks
Mar-30-17 08:30AM  Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to the Companys Strategic and Scientific Advisory Board GlobeNewswire
Mar-22-17 01:06PM  Market Is Home on the Range Again TheStreet.com
Mar-17-17 09:30AM  Today's Research Reports on Biotech Stocks to Watch: Amicus Therapeutics and Sarepta Therapeutics Accesswire
08:30AM  Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference GlobeNewswire
08:16AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : March 17, 2017
Mar-16-17 04:40PM  Why PTC Therapeutics may have to lower the price on a $89,000-a-year drug it just bought at MarketWatch
03:33PM  PTC Therapeutics Buys Duchenne Drug for $140M at Investopedia
Mar-13-17 09:32AM  Sarepta's DMD Drug Launch Slow; What's in Store for 2017?
Mar-10-17 05:57PM  Trump nominates FDA head with deep ties to drug companies Reuters
03:21PM  Payor Re-Evaluation On Exondys Positive For Sarepta
02:33PM  Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease
Mar-07-17 06:48AM  Vetr Advises Hold On Sarepta
Mar-04-17 01:04PM  SAREPTA THERAPEUTICS, INC. Financials
Mar-03-17 11:54AM  Market Action Is Boring but Necessary +5.39%
11:11AM  2 Reasons Behind Sarepta Therapeutics Inc.'s 6.9% February Jump at Motley Fool
09:30AM  Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Sarepta Therapeutics and BioCryst Pharmaceuticals Accesswire
07:23AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : March 3, 2017
Mar-02-17 06:00PM  Sarepta Therapeutics to Present Company Overview at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire +7.41%
04:30PM  Why Abercrombie & Fitch, W&T Offshore, and Sarepta Therapeutics Jumped Today at Motley Fool
11:41AM  Sarepta Therapeutics: What Goes Down Must Go Up at Barrons.com
11:15AM  Shark Bites: Market Taking a Break, but Probably Not for Long
10:42AM  Sarepta Therapeutics, Inc. :SRPT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017
09:23AM  Morning Movers: Shake Shack Sinks, Abercrombie & Fitch Jumps, Valeant Climbs at Barrons.com
08:43AM  Coverage initiated on Sarepta Therapeutics by Instinet
Mar-01-17 04:13PM  Sarepta Stock Seesaws On 2017 Duchenne Muscular Dystrophy Guide
01:00PM  Sarepta Stock Tanks 7% on 4Q Loss at Investopedia
12:56PM  Sarepta Therapeutic shares waver amid concerns over 2017 guidance at CNBC
11:13AM  Sarepta predicts slower sales of Duchenne drug than many investors hoped at bizjournals.com
10:05AM  Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow
09:57AM  The Street Is Misreading Sarepta's Guidance
08:50AM  Edited Transcript of SRPT earnings conference call or presentation 28-Feb-17 9:30pm GMT
08:50AM  Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options
07:40AM  RBC: Sarepta's Setting The Bar Low, Buy On This Weakness
Feb-28-17 07:53PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
06:46PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
04:41PM  Sarepta Therapeutics reports 4Q loss
04:30PM  Sarepta Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today
04:03PM  Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments Business Wire
02:10PM  At rare disease panel, ex-FDA new drug head preaches evidence over empathy at bizjournals.com
07:07AM  Q4 2016 Sarepta Therapeutics Inc Earnings Release - After Market Close
Feb-27-17 08:42AM  Is a Surprise Coming for Sarepta Therapeutics (SRPT) This Earnings Season?
07:50AM  How the states newest Duchenne biotechs are getting a boost from patient groups at bizjournals.com
Feb-24-17 01:17PM  5 Stocks Set for Explosive Breakouts +6.20%
11:44AM  More Selling Pressure, But No Rush for the Exits
Feb-23-17 09:39AM  [2/23] This Weeks Earnings Revisions Movers
Feb-22-17 01:52PM  The Contrary Indicators Are Piling Up +5.93%
09:30AM  Bull Market Ahead for the Biotech Industry in 2017? Today's Reports on Sarepta Therapeutics and Galectin Therapeutics Accesswire
06:43AM  Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
Feb-21-17 02:00PM  Did Gilead's new tool for speeding drug approval come at bargain-basement price? at bizjournals.com
11:03AM  Sarepta Sells Priority Review Voucher for $125M at Investopedia
10:09AM  Sarepta Leads Biotech Movers on Voucher Deal News
10:05AM  Sarepta sells FDA review voucher for $125M, but analyst questions price at bizjournals.com
07:28AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
07:00AM  Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M Business Wire
Feb-17-17 02:30PM  Congressman Keating calls pricy Duchenne drug an example of 'gouging' at bizjournals.com
11:11AM  3 Biotech Stocks to Buy in February at Motley Fool
07:44AM  Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
07:05AM  Santhera opens Mass. office as local Duchenne ecosystem grows at bizjournals.com
Feb-16-17 09:50AM  Oppenheimer Stays Bullish On Sarepta As Concerns Continue To Swirl
Feb-15-17 08:31AM  Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments on February 28, 2017 Business Wire
Feb-14-17 10:48AM  The Fed's Dilemma Is Quite Obvious
10:02AM  Defending Sarepta Against Blowback From the Marathon Pharma Steroid Price Gouging Scandal
Feb-13-17 04:12PM  Marathon Pharma will pause launch of Duchenne muscular dystrophy drug after outcry over $89,000 price at MarketWatch
Feb-10-17 12:04PM  Sarepta Muscular Dystrophy Drug Faces Competition at Investopedia -5.15%
Feb-09-17 03:51PM  FDA approves Marathon Pharma's Duchenne muscular dystrophy drug at MarketWatch
03:13PM  Sarepta Under Pressure As FDA Approves Marathon Pharma's Emflaza For DMD Treatment
Feb-07-17 04:12PM  Why Sarepta Therapeutics, Inc. Stock Rose 13.2% in January at Motley Fool
Feb-02-17 10:53AM  Forget GW Pharmaceuticals -- These 2 Stocks Are Better Buys at Motley Fool
07:21AM  Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
Feb-01-17 01:28PM  Sarepta: It's Not Whether Insurers Will Pay. It's How Much They'll Pay at Barrons.com -6.31%
11:55AM  Sarepta Under Pressure Amid Concerning Exondys 51 Survey Results
Jan-31-17 07:55PM  Catabasis shares plummet on Duchenne trial failure at bizjournals.com +7.21%
05:15PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-23-17 11:12AM  Keep Politics Out Of Science, Says Departing FDA Chief at Forbes
08:25AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : January 23, 2017
Jan-19-17 09:08AM  Catabasis Pharma surges 17% on positive early-stage clinical trial results for DMD drug at MarketWatch
08:40AM  Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; and collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDPresident, CEO & CMONov 09Option Exercise8.283,00024,84075,635Nov 10 08:19 AM
Howton David TSVP, General CounselNov 09Option Exercise23.851,00023,85022,453Nov 10 08:27 AM
Mahatme SandeshSenior Vice President, CFONov 09Option Exercise23.851,00023,85032,532Nov 10 08:26 AM
Ruff ShamimSVP, Regulatory Affairs & QualNov 08Option Exercise26.241,00026,24021,239Nov 10 08:20 AM
Mahatme SandeshSenior Vice President, CFOOct 17Option Exercise13.9030,000417,00061,532Oct 19 04:22 PM
Mahatme SandeshSenior Vice President, CFOOct 17Sale50.0830,0001,502,50231,532Oct 19 04:22 PM
Howton David TSVP, General CounselSep 22Option Exercise13.907,00097,30028,453Sep 26 04:19 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Option Exercise8.2840,179332,682117,162Sep 26 04:23 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Option Exercise13.907,311101,62327,550Sep 30 09:58 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Sale60.007,311438,66020,239Sep 30 09:58 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Sale60.0040,1792,410,74076,983Sep 26 04:23 PM
Howton David TSVP, General CounselSep 22Sale60.007,000420,00021,453Sep 26 04:19 PM
Howton David TSVP, General CounselSep 19Option Exercise13.908,000111,20011,168Sep 21 09:28 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Option Exercise6.9424,352168,94189,983Sep 21 09:29 PM
Aphale JayantVP, Technical OperationsSep 19Option Exercise4.6235,000161,70036,490Sep 21 09:31 PM
Aphale JayantVP, Technical OperationsSep 19Sale50.0035,0001,750,00011,490Sep 21 09:31 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Sale50.0024,3521,217,60076,983Sep 21 09:29 PM
Howton David TSVP, General CounselSep 19Sale50.009,304465,2003,168Sep 21 09:28 PM
Kaye Edward M. MDSVP Interim CEO & CMOSep 14Sale30.0024,557736,71076,983Sep 16 04:04 PM